Radicals, Gene Rewriting and Living Pharmacies: 2026 Blavatnik Laureates Named

Three early-career scientists stood at the center of a black-tie celebration inside the American Museum of Natural History on October 6, each collecting a quarter of a million dollars and a place in the history of one of America’s most distinctive science prizes. David Nagib of The Ohio State University, Patrick Hsu of the Arc Institute and Stanford University, and Jonathan Rivnay of Northwestern University were named the 2026 Laureates of the Blavatnik Awards for Young Scientists, taking home $250,000 each in unrestricted funding for breakthroughs in organic chemistry, genome engineering, and bioelectronics. The ceremony marked the twentieth anniversary of the awards, which were established by the Blavatnik Family Foundation in 2007 and are administered by The New York Academy of Sciences. Hosted by Len and Emily Blavatnik and presented by Robert P. Lifton, President of The Rockefeller University, the gala honored researchers the program describes as America’s most innovative faculty-rank scientists and engineers aged 42 and younger.

The scale of the competition behind this year’s prizes underscores how coveted the awards have become. The 2026 Laureates were selected from a pool of 372 nominees representing 187 academic and research institutions across 43 states. From that national field, an independent jury of eminent scientists chose three winners and 15 Finalists, each of whom received $15,000 in unrestricted funding. Nine honorees of the Blavatnik Regional Awards were also recognized during the evening. For two institutions the night carried special significance: The Ohio State University and the Arc Institute each celebrated their first-ever Blavatnik National Award Laureate, a milestone that signals how the geography of elite early-career research continues to broaden beyond the usual constellation of coastal institutions.

In the chemical sciences, the Laureate is David Nagib, an organic chemist tackling one of the most persistent bottlenecks in medicine: the sheer difficulty of synthesizing complex molecules. Organic synthesis often determines how quickly a promising drug candidate can be made, tested, and improved, and Nagib’s laboratory has focused on harnessing two of chemistry’s most reactive and unruly species, radicals and carbenes, to forge key medicinal building blocks. Radicals and carbenes are notoriously energetic intermediates, capable of transforming molecules in ways that gentler reagents cannot, but historically difficult to control. Nagib’s group has invented methods to activate portions of complex molecules that were previously considered inert, effectively unlocking chemical real estate that synthetic chemists had long been unable to reach.

The significance of that achievement lies in reliability. By converting high-energy chemistry into dependable, reproducible methods, Nagib’s work allows chemists to create more potent and selective medicines faster, cheaper, and more efficiently than conventional routes permit. In practical terms, that means medicinal chemists can explore a wider swath of chemical space when hunting for new drugs, attaching or rearranging molecular features that were once off-limits. The advances are already accelerating pharmaceutical discovery and expanding the boundaries of what modern organic chemistry can accomplish, a contribution the Blavatnik jury singled out in naming him the Chemical Sciences Laureate.

In the life sciences, the Laureate is Patrick Hsu, a bioengineer and co-founder of the Arc Institute whose work sits at the frontier of genome engineering. Biology depends on molecular machines that read, write, and regulate genetic information, and Hsu’s laboratory discovers and engineers these programmable systems to manipulate DNA and RNA with precision. His contributions have widened the CRISPR toolkit with RNA-targeting enzymes, extending gene-editing capability beyond DNA to the transcriptome. More striking still, his team uncovered programmable bridge RNAs, molecules that can direct large-scale genome rewriting by physically bridging a target DNA site with a donor sequence, a mechanism that hints at edits far more ambitious than the small cuts and swaps of first-generation CRISPR tools.

Hsu has also pushed genome engineering into the age of artificial intelligence, pioneering AI models that predict and design biological sequences. Together, these innovations are transforming how scientists approach genome engineering, accelerating biological discovery, and supporting the development of new gene therapies. The Blavatnik citation describes the work as laying the foundation for a new era of AI-enabled biological design, in which computational models and programmable molecular machines work in tandem to rewrite the instructions of life. The recognition is equally a landmark for the Arc Institute, the young Palo Alto research organization Hsu co-founded, which now counts its first Blavatnik National Award Laureate among its ranks.

The Physical Sciences and Engineering Laureate, Jonathan Rivnay, works on a problem that sounds deceptively simple: the human body runs on chemical and ionic signals, but ordinary electronics struggle to read them, let alone join the conversation. A materials scientist and biomedical engineer, Rivnay designs soft, flexible electronic materials that can interface directly with living cells and tissue, bridging the gap between the wet, ionic world of biology and the electronic world of silicon. His devices must conduct ions as well as electrons, bend without breaking, and operate safely within the body, a set of constraints that has driven much of the field of organic bioelectronics in which he has become a leading figure.

Among Rivnay’s most ambitious contributions are implantable devices he helped pioneer known as living pharmacies. These small implants hold engineered cells and prompt them to manufacture and release medicines inside the body, effectively turning a patient’s own therapeutic cells into a controlled drug factory. The approach points toward more personalized treatments for long-term conditions such as cancer, diabetes, and circadian rhythm disorders, diseases in which dosing needs fluctuate and conventional drugs often fall short. By combining flexible electronics with living cells, Rivnay’s research suggests a future in which therapy is delivered on demand, in place, and in tune with the body’s own signals.

The evening was also an occasion for reflection on what two decades of early-career recognition can produce. Lifton, presenting the awards, traced the trajectory of the inaugural cohort of 14 honorees recognized twenty years earlier. Eight of them now hold named and endowed chairs at institutions including Yale, Rockefeller, Cornell, Columbia, and Cambridge. Five have been elected to the U.S. National Academy of Sciences, two to the National Academy of Medicine, six to the American Academy of Arts and Sciences, and one to the Royal Society of the UK. Subsequent to their Blavatnik Awards, members of that first group have won prizes including the Shaw Prize, the Benjamin Franklin Medal, and the Fields Medal, a record that lends weight to the program’s central bet on identifying talent early.

That bet has a well-documented origin story. Nicholas B. Dirks, President and CEO of The New York Academy of Sciences and Chair of the Awards’ Scientific Advisory Council, recalled in his remarks that the idea was inspired by Len Blavatnik’s experience at the 2007 Nobel Prize ceremony, where the prestige of honoring lifelong discoveries prompted a question: what if exceptional scientists could be recognized earlier in their careers, at a pivotal moment when they were just beginning to build their own research programs, pursue ambitious scientific questions, and take creative risks. The Blavatnik Awards were born as a first-of-its-kind science prize dedicated to the most promising early-career scientists of their generation. Since 2007 the program has honored 539 scientists and awarded $21.5 million in unrestricted funding, and it now spans the United States, the United Kingdom, and Israel, awarding more than $2 million annually. At a time when intense competition for research funding makes it increasingly difficult for young investigators to establish independent programs, unrestricted prize money gives recipients freedom to pursue high-risk, high-reward research that conventional grants often cannot support. The economic ripple effects are tangible as well: Blavatnik honorees to date have founded 52 companies, six of them publicly traded, collectively valued at more than $40 billion, evidence that early recognition of scientific talent can translate into discoveries, therapies, and industries that reach far beyond the laboratory.

Subject of Research: The 2026 Blavatnik Awards for Young Scientists honoring early-career research in organic chemistry, genome engineering and bioelectronics

Article Title: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics

Article References: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Blavatnik Awards, David Nagib, Patrick Hsu, Jonathan Rivnay, organic chemistry, CRISPR, bridge RNAs, genome engineering, bioelectronics, living pharmacies, New York Academy of Sciences, early-career scientists